ArticleKidney international reports2017
The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels.
Article in Kidney international reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.QJM : monthly journal of the Association of Physicians · 2020Trial
- Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.Kidney international · 2019Trial
- Effect of plasma sodium concentration on blood pressure regulators during hemodialysis: a randomized crossover study.BMC nephrology · 2018Trial
- Is mild dehydration a risk for progression of childhood chronic kidney disease?Pediatric nephrology (Berlin, Germany) · 2024Review
- The role of copeptin in kidney disease.Endocrine · 2023Review
- Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.Frontiers in pediatrics · 2023Review
- Chronic Lithium Therapy and Urine-Concentrating Ability in Individuals With Bipolar Disorder: Association Between Daily Dose and Resistance to Vasopressin and Polyuria.Kidney international reports · 2022Article
- Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5.BMC nephrology · 2020Article
- Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients.International urology and nephrology · 2019Article
- Osmoregulation Performance and Kidney Transplant Outcome.Journal of the American Society of Nephrology : JASN · 2019Article
- Review
- Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.Cardiovascular diabetology · 2018Observational
- Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.JCI insight · 2018Article
- Angiotensin ATAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCopeptin is increasingly used in epidemiological studies as a substitute for vasopressin. The effect of renal function
methodsCopeptin and vasopressin levels were measured in 127 patients with various stages of chronic kidney disease, including 42 hemodialysis patients and 16 healthy participants in this observational study. Linear (segmental) regression analyses were performed to assess the association between renal function and copeptin, vasopressin and the C/V ratio. In addition, clearance of copeptin and vasopressin by hemodialysis was calculated.
resultsBoth copeptin and vasopressin levels were higher when renal function was lower, and both showed associations with plasma osmolality. The C/V ratio was stable across renal function in subjects with an eGFR >28 ml/min per 1.73 m DISCUSSION: Our data indicate that copeptin is a reliable substitute for vasopressin in subjects with an eGFR >28 ml/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.